サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791755

オミックスに基づく臨床試験の世界市場

Omics-based Clinical Trials

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
オミックスに基づく臨床試験の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

オミックスに基づく臨床試験の世界市場は2030年までに537億米ドルに達する見込み

2024年に352億米ドルと推定されるオミックスに基づく臨床試験の世界市場は、2024年から2030年にかけてCAGR 7.3%で成長し、2030年には537億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるフェーズiは、CAGR 8.6%を記録し、分析期間終了までに233億米ドルに達すると予測されます。フェーズIIセグメントの成長率は、分析期間中CAGR 5.1%と推定されます。

米国市場は93億米ドルと推定、中国はCAGR 7.0％で成長予測

米国のオミックスに基づく臨床試験市場は、2024年に93億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに86億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.9%と6.0%と予測されています。欧州では、ドイツがCAGR 5.7%で成長すると予測されています。

世界のオミックスに基づく臨床試験市場- 主要動向と促進要因のまとめ

なぜオミックスに基づく臨床試験が医薬品開発と精密医療を再定義するのか？

オミックスに基づく臨床試験は、疾患や治療反応の分子的基盤に関する前例のない洞察を提供することで、医薬品開発の状況を一変させています。ゲノム、トランスクリプトーム、プロテオーム、メタボローム、エピゲノムのデータを試験デザインと患者層別化に統合することにより、これらの試験は、薬剤の有効性と安全性を評価するための、より的を絞った、予測的で効率的なアプローチを可能にします。一般化された集団ベースのモデルに大きく依存する従来の臨床試験とは異なり、オミックス情報に基づく臨床試験では、治療反応性と相関する特定のバイオマーカーや分子シグネチャーを同定し、治療から恩恵を受ける可能性が最も高い集団の選択を可能にします。これにより、臨床試験の失敗率が減少し、スケジュールが短縮され、臨床結果が向上します。例えば腫瘍学では、次世代シークエンシング（NGS）は、腫瘍の遺伝子変異に基づいて患者を標的療法や免疫療法に適合させるために日常的に使用されています。同様のアプローチは、神経学、免疫学、希少疾患研究でも普及しつつあります。個別化医療がヘルスケアの中心になるにつれて、企業プロファイルは、有効性だけでなく個々の患者プロファイルに合わせた治療法の開発を目指す製薬企業やバイオテクノロジー企業にとって不可欠なツールになりつつあります。分子診断学を治療評価に統合するその能力は、現代の臨床研究の枠組みそのものを再構築しつつあります。

テクノロジーはどのようにして、より効率的で多次元的な試験デザインを可能にしているのか？

オミックス技術と計算ツールの急速な進歩により、オミックスに基づく臨床試験の設計と実行を大幅に強化しています。ハイスループットシーケンスプラットフォーム、質量分析、シングルセル解析は、複数のオミックス層にわたる生物学的サンプルのより深く正確な特性解析を可能にしています。同時に、ビッグデータ解析、人工知能（AI）、機械学習（ML）は、オミックスデータを解釈し、臨床試験中の意思決定を促進するために使用する方法に革命をもたらしています。これらのツールは、予測バイオマーカーの同定、分子表現型に基づく患者サブグループのクラスタリング、投与量と治療レジメンの最適化を容易にします。デジタルヘルスプラットフォームは現在、リアルタイムのオミックスデータを臨床エンドポイント、ウェアラブルセンサーデータ、電子カルテ（EHR）と統合し、継続的かつ適応的な試験モデルを可能にしています。クラウドベースのバイオインフォマティクス・インフラストラクチャは、安全でスケーラブルかつ協調的なデータ処理を可能にし、世界の多施設オミックス試験をかつてないほど実現可能にしています。さらに、サンプルの保存とロジスティクスの進歩により、生物試料の取り扱いが合理化され、供給源から分析に至るまでデータの質が保証されています。このような技術革新は、オミックスに基づく臨床試験の実現可能性と精度を高めるだけでなく、現代の治療イノベーションの要求を満たす、より機敏で適応性が高く、費用対効果の高い臨床研究環境を後押ししています。

規制当局の支援と産業界の協力がオミックスベースの臨床試験導入を加速しているか？

規制当局からの支援の高まりと業界関係者間の戦略的コラボレーションが、オミックスに基づく臨床試験の採用を大幅に加速しています。FDA、EMA、PMDAのような規制機関は、特に腫瘍学や希少疾患研究において、バイオマーカー主導の試験デザインにますます寛容になってきています。FDAによるRTOR（Real-Time Oncology Review）や画期的治療薬（breakthrough therapy）指定への支援は、オミックスベースのアプローチにより有利な規制環境を作り出しています。さらに、適応試験デザイン、コンパニオン診断薬、治療薬と診断薬のペアの共同開発などに対応できるように規制の枠組みが進化しており、個別化治療の迅速な承認取得が可能となっています。製薬企業、診断薬企業、学術機関、医薬品開発業務受託機関（CRO）間の戦略的パートナーシップは、共有データベースの構築、バイオマーカーの検証、大規模臨床研究をサポートする統合オミックスプラットフォームの構築において極めて重要な役割を果たしています。Cancer MoonshotやAll of Us Research Programのような業界全体のイニシアチブは、オミックス主導型研究のための豊富なデータセットとインフラを提供しています。さらに、特に希少疾患や遺伝性疾患では、患者支援団体が臨床試験のデザインや募集に関与するようになっており、患者中心の包括的な臨床試験が行われるようになっています。規制の枠組みがより敏感になり、生態系がより協調的になるにつれ、オミックスに基づく臨床試験は個別化医薬品開発と治療法検証のゴールドスタンダードとして勢いを増しています。

オミックスに基づく臨床試験市場の世界的拡大の原動力は？

オミックスに基づく臨床試験市場の成長は、技術革新、アンメット・クリニカル・ニーズ、進化する治療モデル、精密医療への投資の増加に根ざした、いくつかの相互に関連する要因によって牽引されています。主要な促進要因の一つは、特に腫瘍学、免疫療法、希少疾患において、従来の画一的なアプローチでは有効性が限定的であった標的治療に対する需要が高まっていることです。ゲノムおよびマルチオミクスデータの爆発的な増加により、研究者はより選択的で仮説に基づいた効率的な臨床試験をデザインできるようになり、臨床成功の確率が向上しています。さらに、製薬企業やバイオテクノロジー企業は、医薬品パイプラインのリスク軽減、患者募集の最適化、バイオマーカー主導の製品差別化による競争優位性を獲得するため、オミックスベースのプラットフォームへの投資を増やしています。NGSとバイオインフォマティクス・ツールの価格が手頃になり、利用しやすくなったことで、中堅企業や学術研究機関全体でオミックス試験機能が民主化されつつあります。一方、特に米国、英国、中国、中東では、集団ゲノミクスと個別化医療を推進する世界のイニシアチブにより、大規模なオミックス対応試験のための強固なインフラと資金基盤が構築されつつあります。適応性のある試験デザインと実世界のエビデンスの統合に対する規制当局の奨励も、承認までの期間を短縮し、業界の信頼を高めています。さらに、個別化された健康、遺伝子検査、疾病予防に関する一般市民の意識の高まりは、より熱心で情報通の患者集団を生み出し、バイオマーカーに基づく試験へのリクルートとリテンションを促進しています。これらの力学が相まって、オミックスに基づく臨床試験市場の世界の拡大が後押しされ、次世代医薬品開発と個別化医療における変革の原動力としての役割が確固たるものとなっています。

セグメント

フェーズ（第I相、第II相、第III相、第IV相）;スタディ（介入研究、観察研究、拡大アクセス研究）;インディケーション（腫瘍適応症、心血管適応症、中枢神経系疾患適応症、疼痛管理適応症、糖尿病適応症、自己免疫/炎症適応症、肥満適応症、その他適応症）

調査対象企業の例

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bristol-Myers Squibb Company
  • Charles River Laboratories
  • Covance Inc.
  • Eli Lilly and Company
  • Fulgent Genetics
  • ICON plc
  • Illumina, Inc.
  • Laboratory Corporation of America
  • Novo Nordisk A/S
  • Parexel International Corporation
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • Pharmaceutical Product Development（PPD）
  • Q2 Solutions
  • Rebus Biosystems, Inc.
  • SGS Societe Generale de Surveillance SA
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32407

Global Omics-based Clinical Trials Market to Reach US$53.7 Billion by 2030

The global market for Omics-based Clinical Trials estimated at US$35.2 Billion in the year 2024, is expected to reach US$53.7 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$23.3 Billion by the end of the analysis period. Growth in the Phase II segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.3 Billion While China is Forecast to Grow at 7.0% CAGR

The Omics-based Clinical Trials market in the U.S. is estimated at US$9.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.6 Billion by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global Omics-Based Clinical Trials Market - Key Trends & Drivers Summarized

Why Are Omics-Based Clinical Trials Redefining Drug Development and Precision Medicine?

Omics-based clinical trials are transforming the landscape of drug development by offering unprecedented insights into the molecular underpinnings of disease and therapeutic response. By integrating genomic, transcriptomic, proteomic, metabolomic, and epigenomic data into trial design and patient stratification, these trials enable more targeted, predictive, and efficient approaches to evaluating drug efficacy and safety. Unlike conventional trials, which rely heavily on generalized population-based models, omics-informed trials identify specific biomarkers or molecular signatures that correlate with treatment response, allowing for the selection of subpopulations most likely to benefit from a therapy. This reduces trial failure rates, accelerates timelines, and enhances clinical outcomes. In oncology, for example, next-generation sequencing (NGS) is routinely used to match patients to targeted therapies or immunotherapies based on their tumor’s genetic mutations. Similar approaches are gaining traction in neurology, immunology, and rare disease studies. As personalized medicine becomes central to healthcare, omics-based clinical trials are becoming indispensable tools for pharmaceutical and biotech companies seeking to develop therapies that are not only effective but also tailored to individual patient profiles. Their ability to integrate molecular diagnostics into therapeutic evaluation is reshaping the very framework of modern clinical research.

How Is Technology Enabling More Efficient, Multi-Dimensional Trial Design?

Rapid advancements in omics technologies and computational tools are significantly enhancing the design and execution of omics-based clinical trials. High-throughput sequencing platforms, mass spectrometry, and single-cell analysis are enabling deeper and more precise characterization of biological samples across multiple omics layers. At the same time, big data analytics, artificial intelligence (AI), and machine learning (ML) are revolutionizing the way omics data is interpreted and used to drive decision-making during clinical trials. These tools facilitate the identification of predictive biomarkers, the clustering of patient subgroups based on molecular phenotypes, and the optimization of dosage and treatment regimens. Digital health platforms are now integrating real-time omics data with clinical endpoints, wearable sensor data, and electronic health records (EHRs), enabling continuous and adaptive trial models. Cloud-based bioinformatics infrastructure allows for secure, scalable, and collaborative data processing, making global, multi-center omics trials more feasible than ever before. Furthermore, advances in sample preservation and logistics are streamlining biospecimen handling, ensuring data quality from source to analysis. These technological innovations are not only driving the feasibility and accuracy of omics-based trials but are also empowering a more agile, adaptive, and cost-effective clinical research environment that meets the demands of modern therapeutic innovation.

Is Regulatory Support and Industry Collaboration Accelerating Omics-Based Trial Adoption?

Growing support from regulatory agencies and strategic collaborations among industry players are significantly accelerating the adoption of omics-based clinical trials. Regulatory bodies like the FDA, EMA, and PMDA are increasingly open to biomarker-driven trial designs, particularly in oncology and rare disease research, where traditional trial structures often fall short. The FDA’s support for Real-Time Oncology Review (RTOR) and breakthrough therapy designations has created a more favorable regulatory climate for omics-based approaches. Moreover, regulatory frameworks are evolving to accommodate adaptive trial designs, companion diagnostics, and the co-development of therapeutic-diagnostic pairs, enabling faster approval pathways for personalized treatments. Strategic partnerships between pharmaceutical companies, diagnostics firms, academic institutions, and contract research organizations (CROs) are playing a pivotal role in creating shared databases, validating biomarkers, and building integrated omics platforms that support large-scale clinical studies. Industry-wide initiatives such as the Cancer Moonshot and the All of Us Research Program are providing rich datasets and infrastructure for omics-driven research. Furthermore, patient advocacy groups are increasingly involved in trial design and recruitment, particularly for rare and genetic diseases, ensuring that trials are patient-centered and inclusive. As regulatory frameworks become more responsive and ecosystems more collaborative, omics-based clinical trials are gaining momentum as the gold standard for personalized drug development and therapeutic validation.

What’s Driving the Global Expansion of the Omics-Based Clinical Trials Market?

The growth in the omics-based clinical trials market is driven by several interrelated factors rooted in technological innovation, unmet clinical needs, evolving therapeutic models, and increased investment in precision medicine. One of the primary drivers is the escalating demand for targeted therapies, especially in oncology, immunotherapy, and rare diseases, where traditional one-size-fits-all approaches have limited efficacy. The explosion of genomic and multi-omics data is enabling researchers to design trials that are more selective, hypothesis-driven, and efficient, improving the probability of clinical success. Additionally, pharmaceutical and biotech companies are increasingly investing in omics-based platforms to de-risk drug pipelines, optimize patient recruitment, and gain competitive advantage through biomarker-driven product differentiation. The increasing affordability and accessibility of NGS and bioinformatics tools are democratizing omics trial capabilities across mid-sized companies and academic research institutions. Meanwhile, global initiatives promoting population genomics and personalized medicine-particularly in the U.S., U.K., China, and the Middle East-are creating a robust infrastructure and funding base for large-scale omics-enabled trials. Regulatory encouragement for adaptive trial designs and real-world evidence integration is also shortening approval timelines and boosting industry confidence. Furthermore, rising public awareness around personalized health, genetic testing, and disease prevention is creating a more engaged and informed patient population, facilitating recruitment and retention in biomarker-based studies. Together, these dynamics are powering the global expansion of the omics-based clinical trials market, cementing its role as a transformative force in next-generation drug development and individualized healthcare.

SCOPE OF STUDY:

The report analyzes the Omics-based Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase (Phase I, Phase II, Phase III, Phase IV); Study (Interventional Studies, Observational Studies, Expanded Access Studies); Indication (Oncology Indication, Cardiovascular Indication, CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bristol-Myers Squibb Company
  • Charles River Laboratories
  • Covance Inc.
  • Eli Lilly and Company
  • Fulgent Genetics
  • ICON plc
  • Illumina, Inc.
  • Laboratory Corporation of America
  • Novo Nordisk A/S
  • Parexel International Corporation
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • Pharmaceutical Product Development (PPD)
  • Q2 Solutions
  • Rebus Biosystems, Inc.
  • SGS Societe Generale de Surveillance SA
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Omics-based Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Emphasis on Precision Medicine Throws the Spotlight on Omics-Based Trials for Targeted Therapeutic Development
    • Biomarker-Driven Patient Stratification Spurs Growth of Genomics and Proteomics Integration in Clinical Trial Design
    • Here's How High-Throughput Sequencing and Molecular Profiling Are Redefining Trial Efficiency and Personalization
    • Increasing Use of Companion Diagnostics Strengthens the Business Case for Omics-Enriched Clinical Pipelines
    • Expansion of Oncology, Neurology, and Rare Disease Trials Accelerates Demand for Multi-Omics-Based Protocols
    • Advancements in AI and Bioinformatics Enable Real-Time Analysis of Omics Data for Adaptive Trial Designs
    • Here's the Story Behind How Multi-Omics Insights Are Enhancing Drug-Target Validation and Therapeutic Predictability
    • Growing Investment in Translational Research and Biobank Infrastructure Expands Addressable Market for Omics Trials
    • Shift Toward Decentralized and Hybrid Clinical Trials Spurs Demand for Remote Omics Sampling and Digital Integration
    • Global Rise in Personalized Drug Development Pipelines Fuels Need for Comprehensive Molecular Endpoint Tracking
    • Emerging Role of Metabolomics and Epigenomics in Chronic Disease Trials Broadens the Omics Application Spectrum
    • Expansion of Population Health Genomics Programs Supports Recruitment and Stratification in Longitudinal Studies
    • Patient Demand for Individualized Therapies Strengthens Adoption of Omics-Based Approaches in Clinical Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Omics-based Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Omics-based Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for CNS Conditions Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for CNS Conditions Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pain Management Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Pain Management Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Diabetes Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Diabetes Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Autoimmune / Inflammation Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Autoimmune / Inflammation Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Obesity Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Obesity Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Oncology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Oncology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cardiovascular Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Cardiovascular Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Interventional Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Interventional Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Observational Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Observational Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Expanded Access Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Expanded Access Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Omics-based Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 34: USA Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • JAPAN
    • Omics-based Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • CHINA
    • Omics-based Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 52: China Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • EUROPE
    • Omics-based Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Omics-based Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • FRANCE
    • Omics-based Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 66: France Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 70: France Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • GERMANY
    • Omics-based Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 72: Germany Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • ITALY
    • TABLE 78: Italy Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 82: Italy Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Italy 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Omics-based Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 84: UK Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 88: UK Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: UK 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of Europe 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Omics-based Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Asia-Pacific 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for Omics-based Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Indication - CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World 6-Year Perspective for Omics-based Clinical Trials by Indication - Percentage Breakdown of Value Sales for CNS Conditions Indication, Pain Management Indication, Diabetes Indication, Autoimmune / Inflammation Indication, Obesity Indication, Other Indications, Oncology Indication and Cardiovascular Indication for the Years 2025 & 2030
    • TABLE 106: Rest of World Recent Past, Current & Future Analysis for Omics-based Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of World 6-Year Perspective for Omics-based Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030

IV. COMPETITION